APOA5 (Apolipoprotein A5)

P2, N=28, Recruiting, University of Texas Southwestern Medical Center | Trial completion date: Dec 2025 --> May 2029 | Trial primary completion date: Sep 2025 --> Aug 2027

P2, N=28, Recruiting, University of Texas Southwestern Medical Center | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Apr 2025 --> Sep 2025

P3, N=30, Active, not recruiting, Visirna Therapeutics HK Limited | Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Jul 2026

Multiple drugs targeting FN1 or ROR1 are available or in clinical trials. These findings suggest that plasma protein FN1 associated with PC holds potential as both prognostic biomarkers and therapeutic targets.

Future directions include validating SELENOP's prognostic and diagnostic value in serum for personalized HCC treatment. Large-scale prospective studies correlating serum SELENOP levels with patient outcomes are essential, along with integrating them with clinical parameters for enhanced prognostic accuracy and tailored therapeutic strategies.

Taken together, this study indicated that PIK3CA-E545K mutation promoted L-OHP resistance by upregulating APOA5 transcription in CRC, which could be a potent target for improving L-OHP chemotherapeutic efficiency. Our study shed light to improve chemotherapy sensitivity through nutrient management in CRC.

P2, N=28, Recruiting, University of Texas Southwestern Medical Center | Not yet recruiting --> Recruiting

This study demonstrates the crucial role of chromosomal structure variation in HCC oncogenesis and potential novel biomarkers of HCC, laying a foundation for cancer precision medicine development.

P2, N=28, Not yet recruiting, University of Texas Southwestern Medical Center | Initiation date: Apr 2023 --> Dec 2023

Knockdown of APOA5 reduced HCC cell proliferation combining with elevating inflammation and ferroptosis levels. In conclusion, we considered APOA5 maybe a novel target for suppressing HCC via simultaneously elevating inflammation and ferroptosis levels, and signature constructed by seven IAF genes including ADH4, APOA5, CFHR3, CXCL8, FTCD, G6PD and PON1 can act as a biomarker for optimising the diagnosis, prognosis evaluation and immunotherapy options in HCC patients.